PHAT - Phathom Pharmaceuticals, Inc.
About Phathom Pharmaceuticals, Inc. (https://www.phathompharma.com)
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Azmi Nabulsi | Co-Founder | 1960 | $1,950,012 USD |
| David A. Socks | Co-Founder | 1975 | $1,950,012 USD |
| Steven L. Basta | Chief Executive Officer, President & Director | 1966 | $1,173,151 USD |
| Anne Marie Cook | Chief Legal Officer & Corporate Secretary | 1962 | $663,406 USD |
| Sanjeev Narula | Chief Financial & Business Officer | 1962 | $644,285 USD |
| Bill Aprea | Senior Vice President, Chief Compliance Officer & Deputy Chief Legal Officer | – | – |
| Eric Sciorilli | Director of Business Development & Investor Relations | – | – |
| Jonathan Bentley | Senior Vice President and Head of Sales, Operations & Training | – | – |
| Nancy R. Phelan | Senior Vice President of Marketing & Analytics | 1969 | – |
| Robert Breedlove | Vice President of Finance & Principal Accounting Officer | – | – |